COO stock forecast, quote, news & analysis

Key Takeaways

• The Cooper Companies posted record Q2 fiscal 2026 revenue of $1.08 billion, up 8% year-over-year, marking its 10th consecutive quarter of beating consensus earnings expectations.
• CooperSurgical is undergoing a strategic review after settling more than 95% of embryo culture media recall claims, with management confirming "robust interest" from potential buyers of the entire business.
• Asia-Pacific revenue declined 6% in Q2, weighed down by consumer softness in Japan and China along with portfolio repositioning away from legacy hydrogel products.
• CooperVision's premium lens portfolio continues to gain momentum, with MyDay delivering double-digit growth and MiSight myopia management lenses surging 24% to $32 million.
• Analyst consensus stands at Hold with an average 12-month price target of approximately $81, while institutional investors remain actively engaged with 24.39% ownership.

Current Market Snapshot

The Cooper Companies (COO) has traded in a relatively measured range over the past 30 days, moving from roughly $71 to the mid-$75 level. The stock has drawn attention from prominent institutional investors including JANA Partners, which increased its position to approximately $255 million, representing 1.83% of the company. The broader medical device sector has navigated mixed macro signals, with tariff concerns and currency fluctuations creating headwinds that partially offset strong underlying demand in vision care and fertility markets. COO's 50-day moving average sits near $69, while the 200-day moving average hovers around $71.50, reflecting a gradual recovery from earlier 2026 lows.

The Cooper Companies (COO) Business Overview and Competitive Position

The Cooper Companies is a global medical device firm headquartered in San Ramon, California, employing more than 15,000 people and selling products in over 130 countries. Its operations are divided into two core segments. CooperVision ranks among the world's largest contact lens manufacturers, controlling roughly one-quarter of the U.S. market with a portfolio spanning spherical, toric, multifocal, and specialty lenses under brands including MyDay, Biofinity, Clariti, and MiSight — the first FDA-approved contact lens designed to slow the progression of childhood myopia. CooperSurgical provides medical devices, fertility consumables, genomics testing, and the PARAGARD hormone-free IUD, which commands approximately 17% of the U.S. IUD market. The company's competitive moat is built on proprietary lens materials, a broad specialty lens portfolio, and the most comprehensive medical device coverage of the entire IVF cycle.

Recent Developments Driving COO

Several meaningful catalysts have shaped investor sentiment around COO. On June 4, the company reported fiscal second-quarter results that exceeded expectations, with non-GAAP EPS of $1.21 compared to the $1.10 consensus and organic revenue growth of 5%. Management also raised free cash flow guidance to approximately $650 million for fiscal 2026. Perhaps most notably, Cooper announced it had resolved embryo culture media recall litigation covering over 95% of claimants, recording a net charge of $271.6 million. This settlement cleared a significant overhang and allowed the company to advance strategic discussions around CooperSurgical, with CEO Albert White indicating "robust interest" from parties seeking to acquire the entire business unit.

On the analyst front, sentiment remains divided but constructive. UBS initiated coverage with a Neutral rating and a $75 price target on July 28. Mizuho and BNP Paribas Exane reiterated Outperform ratings with price targets of $85 and $92, respectively, while Piper Sandler maintained an Overweight rating with an $86 target. Meanwhile, Goldman Sachs set a more cautious $61 target, and JPMorgan lowered its target to $71, citing valuation and macro concerns. The company is scheduled to report third-quarter fiscal 2026 results on September 9, which will provide further clarity on Asia-Pacific performance and the CooperSurgical strategic review timeline.

Trending AI Robots

For traders seeking data-driven market insights, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that actively trade thousands of tickers across various strategies, timeframes, and performance profiles. The Trending AI Robots section highlights only those bots demonstrating the strongest recent performance and highest relevance to current market conditions, enabling users to explore algorithmic trading approaches without sifting through the full bot catalog. Whether you are interested in short-term momentum strategies, swing trading, or longer-term thematic exposure, this page provides a practical entry point for evaluating AI-driven trading solutions.

2026 Outlook and What Investors Should Watch

The remainder of fiscal 2026 presents several critical checkpoints for Cooper Companies investors. The September 9 earnings release will reveal whether Asia-Pacific headwinds are stabilizing and whether portfolio repositioning efforts are gaining traction. The CooperSurgical strategic review remains the most consequential catalyst — a potential sale could unlock significant shareholder value, while a decision to retain the business would refocus attention on organic execution. Contact lens demand trends bear close monitoring, particularly the ongoing consumer shift toward premium daily silicone hydrogel products like MyDay and the international expansion of MiSight. Tariff developments, currency fluctuations, and broader healthcare spending patterns in the U.S., Europe, and Asia will also influence near-term performance. With management guiding to fiscal 2026 revenue of $4.28 billion to $4.32 billion and non-GAAP EPS of $4.58 to $4.66, execution against these targets will be closely scrutinized against a backdrop of mixed global economic conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations